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Abstract
Aims Diabetic microvascular complications of retinopathy, nephropathy and neuropathy may occur at hemoglobin A1c 
levels (HbA1c) below the 6.5% (48 mmol/mol) diagnostic threshold. Our objective was to assess the validity of the HbA1c 
diagnostic cutpoint of 6.5% based upon published evidence of the prevalence of retinopathy, nephropathy and neuropathy 
as markers of diabetes.
Methods Data Sources PubMed, Embase, Cochrane, Scopus and CINAHL from 1990-March 2019, grey literature sources. 
Study Selection All studies reported after 1990 (to ensure standardized HbA1c values) where HbA1c levels were presented 
in relation to prevalence of retinopathy, nephropathy or neuropathy in subjects not known to have diabetes. Data Extraction 
Studies were screened independently, data abstracted, and risk of bias appraised. Data Synthesis Data were synthesized using 
HbA1c categories of < 6.0% (< 42 mmol/mol), 6.0–6.4% (42–47 mmol/mol) and ≥ 6.5% (≥ 48 mmol/mol). Random-effects 
meta-analyses were conducted for retinopathy, nephropathy and neuropathy prevalence stratified by HbA1c categories. 
Random-effects multivariable meta-regression was conducted to identify predictors of retinopathy prevalence and sources 
of between-study heterogeneity.
Results Pooled mean prevalence was: 4.0%(95% CI: 3.2–5.0%) for retinopathy, 10.5% (95% CI: 4.0–19.5%) for nephropathy, 
2.5% (95% CI: 1.1–4.3%) for neuropathy. Mean prevalence when stratified for HbA1c < 6.0%, 6.0–6.4% and ≥ 6.5% was: 
retinopathy: 3.4% (95% CI: 1.8–5.4%), 2.3% (95% CI: 1.6–3.2%) and 7.8%(95% CI: 5.7–10.3%); nephropathy: 7.1% (95% 
CI: 1.7–15.9%), 9.6% (95% CI: 0.8–26.4%) and 17.1% (95% CI: 1.0–46.9%); neuropathy: 2.1% (95% CI: 0.0–6.8%), 3.4% 
(95% CI: 0.0–11.6%) and 2.8% (95% CI: 0.0–12.8%). Multivariable meta-regression showed HbA1c ≥ 6.5% (OR: 4.05; 95% 
CI:  1.92–8.57%), age > 55 (OR: 3.23; 95% CI 1.81–5.77), and African-American race (OR: 10.73; 95% CI: 4.34–26.55), to 
be associated with higher retinopathy prevalence. Marked heterogeneity in prevalence estimates was found across all meta-
analyses (Cochran’s Q-statistic p < 0.0001).
Conclusions The prevalence of nephropathy and moderate retinopathy was increased in subjects with HbA1c values ≥ 6.5% 
confirming the high specificity of this value for diagnosing T2DM; however, at HbA1c < 6.5% retinopathy increased at 
age > 55 years and, most strikingly, in African-Americans, suggesting there may be excess microvascular complication 
prevalence (particularly nephropathy) in individuals below the diabetes diagnostic threshold.
Keywords HbA1c · Type 2 diabetes · Microvascular complications
Introduction
The prevalence of diabetes has reached epidemic propor-
tions globally, with 424.9 million affected adults (20–79 y), 
representing 8.8% of the global adult population. Current 
projections indicate that this figure will rise to 628.6 million 
by the year 2045, affecting almost 10% of the worldwide 
adult population [1]. Type 2 diabetes (T2DM) accounts for 
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the vast majority (90–95%) of diabetes cases and is com-
monly characterized by the inability of pancreatic beta cells 
to meet the demand for insulin secretion due to a relative 
deficit of functional beta cells in a setting of peripheral insu-
lin resistance. There has been much debate over the years as 
to how T2DM should be diagnosed; what should be meas-
ured, and the diagnostic targets have changed, being refined 
as our understanding of the disease has improved along with 
improvement in analytical methods. The diagnostic criteria 
for T2DM are established [2], but it is clear that a continuum 
in blood glucose level exists from normoglycemia to frank 
diabetes. As such, in 1997 and 2003, the Expert Commit-
tee on Diagnosis and Classification of diabetes mellitus 
recognized a cohort of subjects whose glucose levels did 
not meet the criteria for diabetes but were too high to be 
considered as normal [3, 4]; this “prediabetic” group exhib-
ited impaired fasting glucose (IFG) [fasting plasma glucose 
(FPG) levels of 100–125 mg/dL (5.6–6.9 mmol/L) and/or 
impaired glucose tolerance (IGT)] defined as a 2-h plasma 
glucose following a 75 g oral glucose tolerance test (OGTT) 
of 140–199 mg/dL (7.8–11.0 mmol/L)] and represents indi-
viduals at high risk for development of T2DM.
Hemoglobin A1c (HbA1c) is considered key for assess-
ing glycemic control in patients known to have diabetes, 
and several prospective studies using HbA1c have shown 
a strong, continuous association between HbA1c and the 
development of diabetes and complications [5–7]. An Inter-
national Expert Committee (IEC) recommended an HbA1c 
level of 6.5% (48 mmol/mol) as the diagnostic threshold 
for T2DM diagnosis [8], purporting that individuals with 
HbA1c levels above this cutoff have a much higher prob-
ability of having retinopathy than those below. Both the 
American Diabetes Association (ADA) and, subsequently, 
the World Health Organization (WHO) endorsed this opin-
ion, which was entirely based upon the risk of observing 
diabetic retinopathy, without consideration for other diabetic 
microvascular complications; however, the subject has to 
have had diabetes for a period of time for microvascular 
complications to develop that may occur at a lower HbA1c 
than 6.5%.
Key studies contributing to the IEC/ADA/WHO diag-
nostic threshold decision were the results of the cross-sec-
tional Evaluation of Screening and Early Detection Strate-
gies for Type 2 Diabetes and Impaired Glucose Tolerance 
(DETECT-2) study [9] and three epidemiological studies 
undertaken in the 1990s on Pima Indians, Egyptians and 
US subjects enrolled in the National Health and Nutrition 
Examination Survey (NHANES) study [3, 10, 11].
The current HbA1c threshold was based on data available 
at the time of these groups’ reports and, even at the time, 
there was debate as to whether a level of 6.5% (48 mmol/
mol) may be too high since, in many studies, it identified 
fewer patients as having diabetes than the traditional blood 
glucose criteria [12]. Since then, a number of studies have 
been performed with the aim of better characterizing the 
HbA1c threshold for prevalent or incident retinopathy. 
The studies prior to 2013 were summarized in a publica-
tion by Kowall and Rathmann who looked at retinopathy, 
nephropathy and neuropathy [13]; since this time, there have 
been a number of relevant publications which can now be 
considered.
The key aims of this study were to perform a contem-
porary systematic review and meta-analysis to verify the 
HbA1c cutpoint of 6.5% (48 mmol/mol) for the diagnosis of 
T2DM using currently available retinopathy data and, sec-
ondly, to extend the analysis to establish the prevalence of 
nephropathy and neuropathy at differing levels of HbA1c.
Methods
Data sources and search strategy
This systematic review was guided by the Cochrane Collabo-
ration Handbook [14], and followed the Preferred Reporting 
Items for Systematic Reviews and Meta-analyses (PRISMA) 
guidelines [15]. The PRISMA checklist is shown in Sup-
plementary Table 1. A comprehensive systematic search for 
literature was conducted in the academic databases PubMed, 
Embase, Cochrane, Scopus, CINAHL and in sources for 
grey literature in October 2019 (Supplementary Table 2).
Pre-searches to identify relevant search terms, search 
strategies and information sources were performed in 
May–October 2019. PubMed’s MeSH was used to systemati-
cally identify search terms that encompass the variations in 
terminology for glycated hemoglobin, including thresholds 
or cutpoints, as well as terms that describe diabetic micro-
vascular complications (Tables 1, 2, 3). The search strategy 
developed in PubMed was replicated in all databases with 
eventual search terms or technical variations documented 
(Supplementary Table 2). The PRESS peer review of elec-
tronic search strategies: 2015 guideline statement was used 
to peer review the search string [16].
All selected search terms were searched in a combina-
tion of “Abstract” and “Article Title” (alternatively “Topic” 
or “Title, Abstract and Keyword”) and in MeSH/Subject 
Headings/Thesaurus when available. A publication year fil-
ter to include studies from 1990 up to the search date was 
applied to account for the predominant lack of standardized/
harmonized HbA1c measurement before this time. In order 
to ensure literature saturation and inclusion of pre-indexed 
materials, no additional filters or limitations were included.
In addition to the search in academic databases, Open 
Grey, Clinical Trials.gov, The New York Academy of Med-
icine-Grey Literature Report and ProQuest Dissertation and 










































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































the references lists of all studies selected to be included in 
the review was also conducted.
A full search log including search technical details, 
results and notes about search term variations/translations 
for all databases can be found in Supplementary Table 2.
A review protocol for this study was registered in the 
Prospero international prospective register of systematic 
reviews: https ://www.crd.york.ac.uk/prosp ero/displ ay_recor 
d.php?Recor dID=99410 PROSP ERO20 18CRD 42018 09941 
0.
Study selection
Search results were imported into the Covidence systematic 
review tool where duplicate publications were identified and 
duplicates excluded. Study eligibility was independently 
determined by two investigators (AEB and SLA). Where 
there was a discrepancy, both investigators revisited the pub-
lication in question, discussed the results with the group and 
re-entered their decision into the database.
The criterion for inclusion was for a publication to report 
the prevalence of microvascular complications by levels of 
HbA1c. More specifically, studies were only considered if 
they provided a prevalence measure for a microvascular 
complication stratified by HbA1c of < 6% (< 42 mmol/mol), 
6–6.4% (42–47 mmol/mol) and ≥ 6.5% (48 mmol/mol) in the 
same study. The reason for that is to ensure rigor in the asso-
ciation with microvascular complications. Exclusion criteria 
were studies that did not report microvascular complications 
by different HbA1c level and those published before 1990.
For terminology, a “publication” is a document contain-
ing a relevant outcome measure, while a “study” indicates 
all details pertaining to a specific outcome measure—one 
publication may contribute multiple studies. A study, such as 
“prevalence of retinopathy,” could include multiple stratified 
“measures,” such as prevalence by age group.
Data extraction and quality assessment
Following screening of records for eligibility, eligible studies 
had full-text screening (Supplementary Figure 1). Extracted 
variables included: author(s), publication title, year(s) of 
data collection, publication year, country of origin, country 
of survey, study design, study sampling procedure, study 
population and its characteristics (e.g., sex, age and ethnic-
ity), sample size, HbA1c measurement method, HbA1c strat-
ification outcome measures, complications, retinal photogra-
phy method, number of eyes photographed, determination of 
albumin creatinine ratio, measure of peripheral neuropathy. 
Two investigators (AEB and SLA) independently assessed 
the full-text articles and determined the eligibility of studies 
for inclusion in the systematic review.
Quality assessment
Risk of bias (ROB) and precision assessments were per-
formed for all studies included in the review. Guided by the 
Cochrane approach [17], studies were classified as having 
“low” vs. “high” ROB on two quality domains assessing 
(1) consistency in HbA1c diagnostic measurement across 
all study participants (consistent vs. not consistent) and (2) 
rigor of sampling methodology (probability-based vs. non-
probability-based). Studies with unavailable information for 
any given domain were classified as having “unclear” ROB 
for that domain. Studies including at least 100 participants 
were considered as having higher precision. For a prevalence 
of microvascular complications of 1% (see prevalence by 
HbA1c in Table 1) and a sample size of 100, the 95% con-
fidence interval (95% CI) is 0–5%, an acceptable CI for the 
Table 3  Studies included for assessment of HbA1c level and incidence of neuropathy
Authors Title Age Mid-point Age HbA1c Mid-point HbA1c 
cutoff if only range 
given
1 Metcalf PA [38], New 
Zealand
HbA1c in relation to 
incident diabetes and 
diabetes-related compli-
cations in non-diabetic 
adults at baseline





2 Kurisu et al. [50] poster, 
Japan
Polyneuropathy or neu-
ropathic pain did not 
increase at prediabetic 
stage in a Japanese 
population




3 Tapp [49]  Australia Foot complications in type 
2 diabetes: an Australian 
population-based study
 > 25 years Mean age: neu-
ropathy 73 ±10 years; no 
neuropathy 62 ±12 years 
Australia












































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































prevalence of microvascular complications (a lower sample 
size is needed to detect a higher prevalence). Results of the 





Meta-analyses were conducted to estimate the pooled 
mean of diabetes complications in relation to the stratified 
HbA1c values (extracted overall outcome measures for a 
specific HbA1c category, such as 6.0–6.4, were substituted 
with stratified measures such as by sub-levels of HbA1c, 
that is 6.0, 6.1, 6.2…, or population characteristics). For-
est plots were constructed to visualize prevalence measures 
and 95% confidence intervals (CIs) associated with each of 
the three outcomes of interest (retinopathy, nephropathy and 
neuropathy). Estimates for the pooled mean prevalence and 
95% CIs were then calculated using random-effects meta-
analyses. Here, variances of prevalence measures were first 
stabilized using a Freeman–Tukey-type arcsine square-root 
transformation [18, 19]. Inverse variance weighting [19, 20] 
was subsequently applied prior to pooling estimates using a 
DerSimonian–Laird random-effects model [21]. This model 
assumes a normal distribution for true effect sizes (preva-
lence) across studies and thus factors in sampling variation 
and true heterogeneity in effect size [22].
A heterogeneity assessment was further conducted using 
Cochran’s Q statistic to confirm existence of heterogeneity 
across studies and  I2 to quantify magnitude of between-study 
variation that is due to true differences in effect size rather 
than chance [22, 23].
Meta-analyses were implemented in R version 3.4.2 [24].
Meta‑regression methodology
Associations with prevalence and sources of between-study 
heterogeneity were identified using random-effects univari-
able and multivariable meta-regression analyses. Predictors 
considered a priori included: HbA1c levels, age and race. 
Factors associated with prevalence at p value ≤ 0.10 in uni-
variable analysis were eligible for inclusion in the multi-
variable model. In the latter, a p value ≤ 0.10 but > 0.05 was 
considered as showing “good evidence” for an association 
with prevalence, while a p value ≤ 0.05 indicated strong evi-
dence for an association with prevalence.
The magnitude of the association between these predic-
tors and prevalence was determined by calculating, in the 
univariable analysis, odds ratios (ORs) and their associated 
95% CIs, and in the multivariable analysis, by calculating 
adjusted odds ratios (AORs) and their associated 95% CIs.
Meta-regressions were conducted in Stata/SE version 13 
[25] using the metareg package [26].
Results
Literature search
A total of 12,845 references were identified through the 
literature search and uploaded to the systematic review 
software Covidence for de-duplication and screening. 9370 
references (9324 from the database search and 46 from the 
grey literature search) qualified for title and abstract screen-
ing after de-duplication. The screening process in Covidence 
software was blinded. Of the 9370 references, 9206 records 
were excluded. 164 full-text articles were then assessed for 
eligibility; of those 135 were excluded because of insuffi-
cient details of the relationship of the microvascular compli-
cation to the HbA1c values less than 6.5% (48 mmol/mol). 
Twenty nine publications remained eligible for inclusion in 
the systematic review, 22 relating to retinopathy (Table 1) 
[6, 9, 11, 27–46]; 4 relating to nephropathy (Table 2) [28, 38, 
47, 48] and 3 relating to neuropathy (Table 3) [38, 49, 50]. 
No additional relevant references were identified in the hand 
searching of the reference lists of the 29 included studies. 
The retinopathy studies contributed 74 stratified measures 
for the quantitative meta-analysis according to HbA1c as 
detailed above.
Study characteristics
The definitions of retinopathy, nephropathy and neurop-
athy used in each study are shown in Tables 1, 2 and 3, 
respectively.
Diabetic retinopathy, defined as diabetes-related damage 
to the retina, is classified into early stage non-proliferative 
diabetic retinopathy (NPDR, comprising microaneurysms 
and macular edema) and second-stage proliferative diabetic 
retinopathy (PDR, comprising neovascularization and vit-
reous hemorrhages) and fundal photography is required 
for diagnosis [51]. HbA1c was stratified into the following 
categories in each study: < 6% (< 42 mmol/mol),  = 6–6.4% 
(42–47 mmol/mol) and  ≥ 6.5% (≥ 48 mmol/mol).
The forest plot for retinopathy is shown in Fig.  1. 
The median prevalence of retinopathy was overall 4.0% 
(range: 0–48.3%), but varied according to HbA1c levels 
(Table 4). It was 2.7% (range: 0–15.9%) for HbA1c < 6.0% 
(< 42  mmol/mol), 1.2% (range: 0.2–14.8%) for HbA1c 
6.0–6.4% 42–47 mmol/mol) and 5.6% (range: 0.4–48.3%) 
for HbA1c ≥ 6.5% (≥ 48 mmol/mol).
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Fig. 1  Forest plot showing 
results of the meta-analysis for 
retinopathy prevalence. Retin-




The forest plot for nephropathy is shown in Fig. 2. The 
median prevalence of nephropathy was assessed at 11.2% 
(range: 0.9–32.6%). However, there was also variability 
based on HbA1c value, with a median of 7.3% (range: 
1.0–19.7%) for HbA1c < 6.0% (< 42 mmol/mol), 12.4% 
(range: 0.9–18.5%) for HbA1c 6.0–6.4% (42–47 mmol/
mol) and 26.0% (range: 1.9–32.6%) for HbA1c ≥ 6.5% 
(≥ 48 mmol/mol) (Table 4).
The forest plot for neuropathy is shown in Fig. 3. The 
median prevalence for neuropathy was 3.9% (range: 
0.2–8.5%). It was 2.8% (range: 0.2–5.0%) for HbA1c < 6.0% 
(< 42  mmol/mol), 5.6% (range: 0.2–8.5%) for HbA1c 
6.0–6.4% (42–47 mmol/mol) and 3.8% (range: 0.2–8.5%) 
for HbA1c ≥ 6.5% (≥ 48 mmol/mol) (Table 4).
Quality assessment
Supplementary Tables 3 and 4 show the results of the sum-
marized and study-specific quality assessments. In sum, 
72.7% (n = 16 out of 22) of retinopathy studies, 50.0% (n = 2 
out of 4) of nephropathy studies and 66.7% (n = 2 out of 3) 
of neuropathy studies included at least 100 participants and 
therefore were considered as having higher precision.
Low risk of bias, assessed as consistency in measuring 
HbA1c across study participants, was found in 81.8% of 
studies assessing retinopathy, all studies assessing nephropa-
thy, and 66.7% of studies assessing neuropathy. The major-
ity of studies assessing retinopathy (95.5%) and all studies 
assessing nephropathy and neuropathy used probability-
based sampling and hence were also classified as having 
low ROB on that quality domain.
Overall, studies reporting the prevalence of microvas-
cular complications of T2DM were of acceptable quality: 
81.8% of retinopathy studies, all nephropathy studies and 
66.7% of neuropathy studies had low ROB on both quality 
domains. High ROB on both domains was found in only 
4.5% of retinopathy studies and none of nephropathy or neu-
ropathy studies.
Meta‑analysis results
The pooled mean prevalence was estimated at 4.1% (95% CI: 
3.2–5.0%) for retinopathy, 10.5% (95% CI: 4.4–18.8%) for 
nephropathy and 2.5% (95% CI: 1.1–4.3%) for neuropathy 
(Table 4 and Figs. 1, 2, 3).
There was evidence for heterogeneity in prevalence 
estimates across all meta-analyses (Table  4). P value 
for Cochran’s Q statistic was almost always < 0.0001. I2 
was > 90% indicating that most variability is due to true dif-
ferences in prevalence across studies rather than chance.
Fig. 2  Forest plot showing results of the meta-analysis for nephropathy prevalence. Nephropathy prevalence stratified by HbA1c levels
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HbA1c Level and risk of retinopathy
For retinopathy, when the prevalence of complications was 
stratified according to HbA1c, using categories of < 6.0% 
(< 42 mmol/mol), 6.0–6.4% (42–46 mmol/mol) and ≥ 6.5% 
(≥ 48 mmol/mol), there was a distinct increase in retin-
opathy prevalence from a pooled mean of 3.41% (95% CI: 
1.84–5.42) in the < 6.0% (< 42 mmol/mol) stratum and a 
pooled mean of 2.40% (95% CI: 1.65–3.29) in the 6–6.4% 
42–47 mmol/mol) stratum to a pooled mean of 7.97% (95% 
CI: 5.70–10.57) in the ≥ 6.5% (≥ 48 mmol/mol) stratum. The 
J-shaped curve describing this association can be found in 
Fig. 4. The prevalence of retinopathy stratified in 0.1% incre-
ments is shown in Fig. 5. The latter analysis showed no trend 
of increasing retinopathy for HbA1c ranging from 6.0 to 
6.4%, but a marked increase in prevalence at HbA1c of 6.5% 
and greater.
HbA1c Level and risk of nephropathy
The albumin/creatinine ratio (expressed as mg albumin: 
mmol creatinine; ACR) is a sensitive indicator of kidney dis-
ease, and patients are classified according to the 2012 guide-
lines developed by the Kidney Disease: Improving Global 
Outcomes organization (KDIGO) [52] as: normal < 3 mg/
mmol (A1), moderate 3–30 mg/mmol (A2), severe > 30 mg/
mmol (A3; nephropathy). Notably, for nephropathy, the 
prevalence of this complication overall tended to be higher 
than that for retinopathy. Again, there was a distinct increase 
in nephropathy prevalence from a pooled mean of 7.12% 
(95% CI: 1.68–15.85) in the < 6.0% (< 42 mmol/mol) stra-
tum and a pooled mean of 9.56% (95% CI: 0.75–26.41) in 
the 6–6.4% (42–47 mmol/mol) stratum to a pooled mean 
of 17.10% (95% CI: 0.96–46.85) in the ≥ 6.5% (≥ 48 mmol/
mol) stratum.
HbA1c Level and risk of neuropathy
Diabetic neuropathy, defined as the signs and symptoms 
of neuropathy wherein diabetes is the underlying cause, 
most frequently manifests as a distal, symmetric deficit 
[53]. For neuropathy, no trend in the pooled mean was seen 
when stratified according to HbA1c: < 6.0% (< 42 mmol/
mol) (pooled mean of 2.06%; 95% CI: 0.02–6.76), 
6–6.4% (42–47 mmol/mol) (pooled mean 3.39%; 95% CI: 
0.00–11.55) and ≥ 6.5% (≥ 48 mmol/mol) (pooled mean 
2.81%; 95% CI: 0.00–12.77). This may, however, be due to 
the paucity of studies available.




As a higher prevalence of complications may be antici-
pated with increasing age, the meta-analysis data of stud-
ies reporting retinopathy were stratified by age using both 
two strata (age ≤ 55 years and > 55 years) and three strata 
(age ≤ 55 years, age 55–59 years and > 60 years) with levels 
of HbA1c (Table 5). As anticipated, the pooled means did 
tend to increase with age, though this trend did not differ 
substantially from the original analysis.
Certain ethnic populations are also known to develop dia-
betes complications more frequently, notably African-Amer-
icans [46]. A sensitivity analysis was therefore performed 
on the results of the meta-analysis for studies reporting 
retinopathy separately for African-Americans and non-Black 
populations (Table 6). The results showed the same upward 
trend for retinopathy with increasing levels of HbA1c in both 
the Black and non-Black populations, though the African-
Americans populations had a notably higher prevalence 
of retinopathy at every level of HbA1c; the prevalence of 
retinopathy in non-African-Americans in those studies did 
not differ to the overall non-African American prevalence.
There were insufficient studies for both nephropathy and 
neuropathy to perform subgroup analyses.
Meta‑regression results
Only retinopathy prevalence had a sufficient number of stud-
ies to warrant conduct of meta-regression analysis (Table 7).
The univariable analysis showed an association with prev-
alence for HbA1c levels, age and race; these were therefore 
included in the multivariable model. Here, HbA1c stratifica-
tion showed a marked and significant increase of retinopathy 
prevalence at ≥ 6.5% with an AOR of 4.0 (95% CI: 1.9–8.5; 
p < 0.001) after controlling for the confounding effect of age 
and race. The model also showed that individuals > 55 years 
of age had threefold higher odds for retinopathy than 
younger individuals (AOR: 3.3; 95% CI: 1.8–6.0; p < 0.001). 
African-Americans also had significantly higher odds for 
retinopathy prevalence than those of other race (AOR: 11.0; 
95% CI: 4.4–27.5; p < 0.001). This model explained 44.8% 
of the variation in retinopathy prevalence.
Fig. 4  Pooled mean prevalence and adjusted odds ratio of retinopa-
thy according to HbA1c. a Prevalence of retinopathy (%) stratified 
by HbA1c levels of < 6.0%, 6.1–6.4% and 6.5% or greater, showing 
marked increase in retinopathy prevalence in the 6.5% or greater 
group. b Adjusted odds ratio for retinopathy prevalence (for age, sex 
and ethnicity) stratified by HbA1c levels of < 6.0%, 6.1–6.4% and 
6.5% or greater, showing marked increase in the odds ratio in the 
6.5% or greater group
Fig. 5  Pooled mean prevalence of retinopathy stratified in 0.1% incre-
ments of HbA1c. The prevalence of retinopathy stratified in 0.1% 
increments showed no trend of increasing retinopathy for HbA1c 
ranging from 6.0 to 6.4%, but a marked increase in prevalence at 




The meta-analysis relating stratified HbA1c to the preva-
lence of retinopathy, nephropathy and neuropathy showed 
clearly that for moderate retinopathy, the recent data are in 
accord with a HbA1c diagnostic cutoff of 6.5% (48 mmol/
mol and above) for T2DM, with the inflection point for the 
increase in diabetic retinopathy prevalence being at 6.5% 
(48 mmol/mol), as also shown by the stratified analysis 
using the J-shaped curve. Pooled mean retinopathy preva-
lence by 0.1% HbA1c changes showed no obvious signal 
of a rising retinopathy prevalence for HbA1c 6.0 to 6.4%, 
with the inflection point being at 6.5% or greater. This being 
said, there were too few studies assessing retinopathy preva-
lence at HbA1c increments of 6.3% and 6.4% for evidence 
to be conclusive. The latter analysis also showed consider-
able retinopathy prevalence at below 6.0% (42 mmol/mol) 
HbA1c. It should be also emphasized that the stratification 
of HbA1c and retinopathy was based on the detection of 
moderate retinopathy and it is unknown whether the diag-
nostic cutpoint for T2DM may be altered by prevalence stud-
ies on minimal diabetic retinopathy. These results differ from 
that reported in a previous meta-analysis that concluded that 
HbA1c thresholds could not be identified from the studies 
Table 5  Results of meta-analyses of studies reporting retinopathy in patients with different HbA1C stratified by age
a Q: the Cochran’s Q statistic is a measure assessing the existence of heterogeneity in effect size (here, prevalence) across studies
b I2: a measure assessing the magnitude of between-study variation that is due to differences in effect size (here, prevalence) across studies rather 
than chance
Studies Sample Prevalence (%) Heterogeneity measures
Total N Tested Number positive Median Range Pooled mean 95% CI Qa (p value) I2b (%, 95% CI)
Retinopathy
 Age ≤ 55 years
  HbA1C < 6.0 4 9944 160 2.10 0.10–9.70 2.38 0.63–5.16 118.4 
(p < 0.0001)
97.5 (95.6–98.5)
  HbA1C = 6–6.4 15 30,299 274 0.30 0.02–11.60 1.17 0.52–2.07 506.9 
(p < 0.0001)
97.2 (96.4–97.9)




  HbA1C < 6.0 14 53,988 1,548 3.65 0.0–15.90 3.73 1.75–6.37 2166.5 
(p < 0.0001)
99.4 (99.3–99.5)
  HbA1C = 6–6.4 17 61,623 1,415 3.85 0.62–14.80 3.80 2.59–5.23 1001.6 
(p < 0.0001)
98.4 (98.0–98.7)




  HbA1C < 6.0 4 9944 160 2.10 0.10–9.70 2.38 0.63–5.16 118.4 
(p < 0.0001)
97.5 (95.6–98.5)
  HbA1C = 6–6.4 15 30,299 274 0.30 0.02–11.60 1.17 0.52–2.07 506.9 
(p < 0.0001)
97.2 (96.4–97.9)




  HbA1C < 6.0 5 43,074 523 1.45 0.60–6.0 2.29 1.12–3.85 305.3 
(p < 0.0001)
98.7 (98.1–99.1)
  HbA1C = 6–6.4 11 57,555 1,209 3.85 0.99–10.00 3.84 2.47–5.50 788.3 
(p < 0.0001)
98.7 (98.4–99.0)




  HbA1C < 6.0 9 10,914 1,025 5.00 0.00–15.90 4.69 1.58–9.26 637.5 
(p < 0.0001)
98.7 (98.4–99.0)
  HbA1C = 6–6.4 6 4,068 206 3.06 0.62–14.80 3.72 1.22–7.44 119.1 
(p < 0.0001)
95.8 (93.1–97.5)
  HbA1C ≥ 6.5 3 2678 166 6.44 1.57–48.30 10.84 2.65–23.19 53.7 (p < 0.0001) 96.3 (92.1–98.2)
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on microvascular complications, though the threshold of 
HbA1c of 6.5% was strong for severe retinopathy [13].
The heterogeneity in the retinopathy data was controlled 
for in the meta-regression and showed, in both the univariate 
and multivariate analyses, the increased odds ratio of 3.2 and 
4.05, respectively, with an HbA1c of 6.5% or greater; how-
ever, as noted the stratified HbA1c data revealed a J-shaped 
curve showing accountable retinopathy prevalence at below 
6.0%. The meta-regression also revealed the increase in 
retinopathy prevalence with those aged over 55 years, with 
an OR of 3.23 and a striking increase in retinopathy preva-
lence for African-Americans with an OR of 10.73 on mul-
tivariate analysis. While this is in accord with the previous 
data [3, 9–11], retinopathy clearly occurs earlier than the 
cutoff of 6.5%. The magnitude of the association of retin-
opathy with race found here may not be representative as 
only 8 studies were available among African-Americans, 
though it raises the question whether a different diagnostic 
cutoff for T2DM for African-Americans aged greater than 
55 years may be appropriate, as they would appear to be the 
group at greatest risk [54]. It should also be emphasized 
that the stratification of HbA1c and retinopathy was based 
on the detection of moderate retinopathy and it is unknown 
whether the diagnostic cutpoint for T2DM may be altered 
by prevalence studies on minimal diabetic retinopathy. 
Thus, the T2DM diagnostic cutpoint for HbA1c may not be 
a universal “one size fits all,” but may need to be stratified 
according to age and race.
The main limitations of the 22 studies of retinopathy 
included in the meta-analysis were that retinal photography 
was not standardized and that the degree of retinopathy was 
often reported as moderate or poorly specified [27, 38]. As 
different studies have measured the complications in differ-
ent ways, this may have affected the outcome and we may 
therefore have underestimated the prevalence of the diabetic 
complications. There were few studies focusing specifically 
on the onset of minimal diabetes retinopathy. In addition, 
minimal retinopathy may be difficult to differentiate between 
diabetes and non-diabetes-related retinopathy and therefore 
only moderate diabetes changes were identified in all studies 
analyzed. This could suggest that with a standardized proce-
dure specifically identifying minimal diabetic retinopathy, 
that the inflection point for the onset of retinopathy would be 
a HbA1c lower than 6.5% (48 mmol/mol), but this is clearly 
speculative as there is insufficient evidence to support this 
at present.
Four studies were evaluated which considered the onset 
of nephropathy, the data showing that the HbA1c cutoff 
of 6.5% (48 mmol/mol) was appropriate with a significant 
increase in the urine albumin/creatinine ratio. Again, it is 
evident that there were significant numbers of subjects with 
albuminuria in the range of “prediabetes” between 6.0–6.4% 
(42–47 mmol/mol); however, the main limitations were the 
small number of studies, heterogeneity of the population and 
lack of division of the HbA1c level into 0.1% ranges that 
prevented a more stringent determination. In addition, all of 
the studies were cross sectional with a need for longitudinal 
studies to be performed.
There were only three studies with sufficient data that 
could be evaluated for the onset of neuropathy, and these 
Table 6  Sensitivity analysis showing results of meta-analyses of studies reporting retinopathy in patients with different HbA1C excluding Afri-
can-American patients
a Q: the Cochran’s Q statistic is a measure assessing the existence of heterogeneity in effect size (here, prevalence) across studies
b I2: a measure assessing the magnitude of between-study variation that is due to differences in effect size (here, prevalence) across studies rather 
than chance
Studies Sample Prevalence (%) Heterogeneity measures
Total N Tested Number posi-
tive
Median Range Pooled mean 95% CI Qa (p value) I2b (%, 95% CI)
Retinopathy
 Non-African-American
  HbA1C < 6.0 16 63,483 1660 1.88 0.00–15.90 2.79 1.34–4.72 2232.1 
(p < 0.0001)
99.3 (99.2–99.4)
  HbA1C = 6–6.4 29 90,744 1548 1.07 0.02–10.00 1.87 1.22–2.64 1599.7 
(p < 0.0001)
98.2 (97.9–98.5)




  HbA1C < 6.0 2 449 48 12.05 9.70–14.40 11.14 6.98–16.09 1.8 (p = 0.1793) 44.6 (–)
  HbA1C = 6–6.4 3 1178 141 11.6 10.90–14.80 11.89 10.09–13.81 1.7 (p = 0.4192) 0.0 (0.0–88.0)





were inconclusive with no inflection point seen for the 
HbA1c cutoff, with a prevalence of neuropathy at an HbA1c 
of 6.0–6.4 (42–46 mmol/mol) being the same as that of 6.5% 
(48 mmol/mol) and above. The main limitations here include 
the limited amount of data in too few studies, heterogeneity 
of the population and poor division of the HbA1c range into 
0.1% ranges; however, given the limited data, it is unlikely 
that division of HbA1c into 0.1% ranges would have allowed 
a more stringent determination.
Conclusions
In conclusion, based on the strongest data of moderate retin-
opathy, this systematic review and meta-analysis is in accord 
that the HbA1c diagnostic cutpoint of 6.5% (48 mmol/
mol) is highly specific for diagnosing T2DM, though the 
increased prevalence of retinopathy in those aged 55 years 
or greater and in African-Americans may suggest a lower 
threshold is appropriate for those groups. However, this 
analysis highlights that diabetic microvascular complications 
commonly occur at lower HbA1c values, and the sensitivity 
of diagnosing T2DM may improve with a lower diagnostic 
cutpoint. There is a need for studies that standardize the 
definition of minimal diabetic retinopathy with more sensi-
tive measures of nephropathy and neuropathy to determine 
if a lower threshold is appropriate.
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